GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (FRA:BX2) » Definitions » Accounts Payable

BioXcel Therapeutics (FRA:BX2) Accounts Payable : €13.42 Mil (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics Accounts Payable?

BioXcel Therapeutics's Accounts Payable for the quarter that ended in Sep. 2024 was €13.42 Mil.

BioXcel Therapeutics's quarterly Accounts Payable declined from Mar. 2024 (€15.84 Mil) to Jun. 2024 (€12.32 Mil) but then increased from Jun. 2024 (€12.32 Mil) to Sep. 2024 (€13.42 Mil).

BioXcel Therapeutics's annual Accounts Payable increased from Dec. 2021 (€4.14 Mil) to Dec. 2022 (€9.66 Mil) and increased from Dec. 2022 (€9.66 Mil) to Dec. 2023 (€12.52 Mil).


BioXcel Therapeutics Accounts Payable Historical Data

The historical data trend for BioXcel Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioXcel Therapeutics Accounts Payable Chart

BioXcel Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Payable
Get a 7-Day Free Trial 4.46 3.27 4.14 9.66 12.52

BioXcel Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.00 12.52 15.84 12.32 13.42

BioXcel Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.


BioXcel Therapeutics Accounts Payable Related Terms

Thank you for viewing the detailed overview of BioXcel Therapeutics's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


BioXcel Therapeutics Business Description

Traded in Other Exchanges
Address
555 Long Wharf Drive, New Haven, CT, USA, 06511
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

BioXcel Therapeutics Headlines

No Headlines